A Study of XZP-3621 in Chinese Patients With ALK Positive NSCLC
Status:
Not yet recruiting
Trial end date:
2025-07-01
Target enrollment:
Participant gender:
Summary
This was a single-arm, open-label, multicenter, phase II study to evaluate the efficacy and
safety of the ALK inhibitor XZP-3621 when used as single agent in patients with
ALK-rearranged stage IIIB, IIIC or IV NSCLC previously treated with other ALK inhibitors or
non-previously treated.